<?xml version="1.0" encoding="UTF-8"?>
<doc:document xmlns:doc="http://www.elsevier.com/xml/document/schema"
              xmlns:dp="http://www.elsevier.com/xml/common/doc-properties/schema"
              xmlns:cps="http://www.elsevier.com/xml/common/consyn-properties/schema"
              xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
              xmlns:dct="http://purl.org/dc/terms/"
              xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
              xmlns:oa="http://vtw.elsevier.com/data/ns/properties/OpenAccess-1/"
              xmlns:bam="http://vtw.elsevier.com/data/voc/ns/bam-vtw-1/"
              xmlns:cp="http://vtw.elsevier.com/data/ns/properties/Copyright-1/"
              xmlns:cja="http://www.elsevier.com/xml/cja/schema"
              xmlns:ja="http://www.elsevier.com/xml/ja/schema"
              xmlns:bk="http://www.elsevier.com/xml/bk/schema"
              xmlns:ce="http://www.elsevier.com/xml/common/schema"
              xmlns:mml="http://www.w3.org/1998/Math/MathML"
              xmlns:cals="http://www.elsevier.com/xml/common/cals/schema"
              xmlns:tb="http://www.elsevier.com/xml/common/table/schema"
              xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/schema"
              xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/schema"
              xmlns:xlink="http://www.w3.org/1999/xlink">
   <rdf:RDF>
      <rdf:Description rdf:about="http://dx.doi.org/10.1016/j.phyplu.2021.100141">
         <dct:format>application/xml</dct:format>
         <dct:title>4-HIL mitigates type-2 diabetic complications through inhibiting inflammation and Nrf2 mediated oxidative stress in rats</dct:title>
         <dct:creator>Rupali Singh</dct:creator>
         <dct:creator>Karan Singh Yadav</dct:creator>
         <dct:creator>Ramanand Prajapati</dct:creator>
         <dct:creator>Sharad Sharma</dct:creator>
         <dct:creator>Srikanta Kumar Rath</dct:creator>
         <dct:creator>Tadigoppula Narender</dct:creator>
         <dct:creator>Madhav Nilakanth Mugale</dct:creator>
         <dct:subject>
            <rdf:Bag>
               <rdf:li>4-hydroxyisoleucine</rdf:li>
               <rdf:li>Antioxidant</rdf:li>
               <rdf:li>Diabetic complication</rdf:li>
               <rdf:li>Inflammation</rdf:li>
               <rdf:li>Oxidative stress</rdf:li>
            </rdf:Bag>
         </dct:subject>
         <dct:description>Phytomedicine Plus 2 (2022). doi:10.1016/j.phyplu.2021.100141</dct:description>
         <prism:aggregationType>journal</prism:aggregationType>
         <prism:publicationName>Phytomedicine Plus</prism:publicationName>
         <prism:copyright>© 2021 The Author(s). Published by Elsevier B.V.</prism:copyright>
         <dct:publisher>Elsevier B.V.</dct:publisher>
         <prism:issn>2667-0313</prism:issn>
         <prism:volume>2</prism:volume>
         <prism:number>1</prism:number>
         <prism:coverDisplayDate>February 2022</prism:coverDisplayDate>
         <prism:doi>10.1016/j.phyplu.2021.100141</prism:doi>
         <prism:url>http://dx.doi.org/10.1016/j.phyplu.2021.100141</prism:url>
         <dct:identifier>doi:10.1016/j.phyplu.2021.100141</dct:identifier>
         <bam:articleNumber>100141</bam:articleNumber>
         <oa:openAccessInformation>
            <oa:openAccessStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://vtw.elsevier.com/data/voc/oa/OpenAccessStatus#Full</oa:openAccessStatus>
            <oa:openAccessEffective xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">2021-10-21T13:24:57Z</oa:openAccessEffective>
            <oa:sponsor xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
               <oa:sponsorType>http://vtw.elsevier.com/data/voc/oa/SponsorType#Author</oa:sponsorType>
            </oa:sponsor>
            <oa:userLicense xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://creativecommons.org/licenses/by/4.0/</oa:userLicense>
         </oa:openAccessInformation>
         <cp:licenseLine xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">This is an open access article under the CC BY license.</cp:licenseLine>
      </rdf:Description>
   </rdf:RDF>
   <dp:document-properties>
      <dp:aggregation-type>Journals</dp:aggregation-type>
      <dp:version-number>S300.1</dp:version-number>
   </dp:document-properties>
   <ja:article docsubtype="fla" version="5.6" xml:lang="en">
      <ja:item-info>
         <ja:jid>PHYPLU</ja:jid>
         <ja:aid>100141</ja:aid>
         <ce:article-number>100141</ce:article-number>
         <ce:pii>S2667-0313(21)00123-8</ce:pii>
         <ce:doi>10.1016/j.phyplu.2021.100141</ce:doi>
         <ce:copyright type="other" year="2021">The Author(s)</ce:copyright>
      </ja:item-info>
      <ja:head>
         <ce:dochead id="dchd0001">
            <ce:textfn id="dhtxt0001">Research article</ce:textfn>
         </ce:dochead>
         <ce:title id="tte0002">4-HIL mitigates type-2 diabetic complications through inhibiting inflammation and Nrf2 mediated oxidative stress in rats</ce:title>
         <ce:author-group id="aut0001">
            <ce:author id="au0001"
                       author-id="S2667031321001238-d77a017e14c04a2b3597feb04b607b78">
               <ce:given-name>Rupali</ce:given-name>
               <ce:surname>Singh</ce:surname>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0002"
                       author-id="S2667031321001238-659366b78591a1512269d0b1a7ddd6f9">
               <ce:given-name>Karan Singh</ce:given-name>
               <ce:surname>Yadav</ce:surname>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0003"
                       author-id="S2667031321001238-5f269f402dc5867762a1bee9729a93f0">
               <ce:given-name>Ramanand</ce:given-name>
               <ce:surname>Prajapati</ce:surname>
               <ce:cross-ref refid="aff0002">
                  <ce:sup loc="post">b</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0004"
                       author-id="S2667031321001238-c3c5f05e79a01db5b5a787531b71e02d">
               <ce:given-name>Sharad</ce:given-name>
               <ce:surname>Sharma</ce:surname>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0005"
                       author-id="S2667031321001238-470b0c0e6f40c9ff60d5b46d0f1e0f80">
               <ce:given-name>Srikanta Kumar</ce:given-name>
               <ce:surname>Rath</ce:surname>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0006"
                       author-id="S2667031321001238-8ec7271a6fa7d30db37f7843948b4611">
               <ce:given-name>Tadigoppula</ce:given-name>
               <ce:surname>Narender</ce:surname>
               <ce:cross-ref refid="aff0002">
                  <ce:sup loc="post">b</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0007"
                       author-id="S2667031321001238-9c893250178122d6a1e684e60699d00a">
               <ce:given-name>Madhav Nilakanth</ce:given-name>
               <ce:surname>Mugale</ce:surname>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="cor0001">
                  <ce:sup loc="post">⁎</ce:sup>
               </ce:cross-ref>
               <ce:e-address id="ead0001"
                             type="email"
                             xlink:href="mailto:madhav.mugale@cdri.res.in">madhav.mugale@cdri.res.in</ce:e-address>
            </ce:author>
            <ce:affiliation id="aff0001"
                            affiliation-id="S2667031321001238-71b956865ca0a70b67d42a4567ad509a">
               <ce:label>a</ce:label>
               <ce:textfn id="cetextfn0001">Division of Toxicology and Experimental Medicine</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Division of Toxicology and Experimental Medicine</sa:organization>
               </sa:affiliation>
               <ce:source-text id="staff0001">Division of Toxicology and Experimental Medicine</ce:source-text>
            </ce:affiliation>
            <ce:affiliation id="aff0002"
                            affiliation-id="S2667031321001238-5c2992b086de3e1bfcdfd533cb3791ee">
               <ce:label>b</ce:label>
               <ce:textfn id="cetextfn0001q">Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, India, 226 031</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Division of Medicinal and Process Chemistry</sa:organization>
                  <sa:organization>CSIR-Central Drug Research Institute (CSIR-CDRI)</sa:organization>
                  <sa:city>Lucknow</sa:city>
                  <sa:postal-code>226 031</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
               <ce:source-text id="staff0001q">Process Chemistry, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, India, 226 031</ce:source-text>
            </ce:affiliation>
            <ce:correspondence id="cor0001">
               <ce:label>⁎</ce:label>
               <ce:text id="cetext0001">Corresponding author: CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, India.</ce:text>
               <sa:affiliation>
                  <sa:organization>CSIR-Central Drug Research Institute (CSIR-CDRI)</sa:organization>
                  <sa:city>Lucknow</sa:city>
                  <sa:country>India</sa:country>
               </sa:affiliation>
            </ce:correspondence>
         </ce:author-group>
         <ce:date-received day="25" month="8" year="2021"/>
         <ce:date-revised day="11" month="10" year="2021"/>
         <ce:date-accepted day="21" month="10" year="2021"/>
         <ce:abstract id="abs0001" class="author-highlights" view="all">
            <ce:section-title id="cesectitle0001">Hightlights</ce:section-title>
            <ce:abstract-sec id="abss0001" view="all">
               <ce:simple-para id="spara007" view="all">
                  <ce:list id="celist0001">
                     <ce:list-item id="celistitem0001">
                        <ce:label>•</ce:label>
                        <ce:para id="para0001" view="all">4-HIL improves body weights in diabetic control animals.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0002">
                        <ce:label>•</ce:label>
                        <ce:para id="para0002" view="all">Treatment with 4-HIL significantly reduced the hyperglycaemia by 75.19%, glycated hemoglobin by 22.98%, creatinine, blood urea nitrogen, and triglyceride when compared with diabetic animals.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0003">
                        <ce:label>•</ce:label>
                        <ce:para id="para0003" view="all">DN leads structural and functional kidney(s) abnormalities and in DR alteration in the retinal blood vessels leads to leakage. Special staining PAS and Massons trichrome showed accumulation of glycogen and collagen formation; whereas reduced in expression in treated animals. Retinal and corneal damage in eye of diabetic rats and reduced and restored structure and function near to normal treated.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0004">
                        <ce:label>•</ce:label>
                        <ce:para id="para0004" view="all">In western blot analysis expression of TIM-1, VEGF decreases on 4HIL treatment and there was increase in Insulin R expression.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0005">
                        <ce:label>•</ce:label>
                        <ce:para id="para0005" view="all">4-HIL alleviates the diabetic nephropathy and retinopathy.</ce:para>
                     </ce:list-item>
                  </ce:list>
               </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract id="abs0002" view="all" class="author">
            <ce:section-title id="cesectitle0002">Abstract</ce:section-title>
            <ce:abstract-sec id="abss0003" role="background" view="all">
               <ce:section-title id="cesectitle0003">Background</ce:section-title>
               <ce:simple-para id="spara008" view="all">Hyperglycemia induced diabetic complications as well as dysfunction of multiple organs is closely related to the increased inflammation and oxidative stress (OS). 4-hydroxyisoleucine (4-HIL), a major constituent of Trigonella foenum-graecum L. shown to have anti-diabetic effects. However, its potential mechanism against diabetic complications in the model of metabolic syndrome have not yet been characterized.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0004" view="all">
               <ce:section-title id="cesectitle0004">Purpose</ce:section-title>
               <ce:simple-para id="spara009" view="all">The present study aimed to investigate the ameliorative effects of 4-HIL in rat model of metabolic syndrome and to explore the possible mechanism of action.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0005" role="materials-methods" view="all">
               <ce:section-title id="cesectitle0005">Methods</ce:section-title>
               <ce:simple-para id="spara010" view="all">Male Sprague dawley rat of 6 -7 weeks were administrated with 4-HIL by oral gavage from 12 to 20 weeks after development of complications. At the end of the study, all animals were sacrificed. Tissues and blood samples were collected for histopathologic and biochemical analysis. Serum metabolic parameters, level of triglycerides, glycated hemoglobin, activities of antioxidant enzymes were estimated. Pathological changes in the tissues were assessed by Hematoxylin – Eosin (H &amp; E), Masson's trichrome and Periodic Acid - Schiff (PAS) staining. In vivo gene expressions were demonstrated by Western blotting.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0006" role="results" view="all">
               <ce:section-title id="cesectitle0006">Results</ce:section-title>
               <ce:simple-para id="spara011" view="all">Oral administration of 4-HIL (200 mg kg−1) reduced the body hyperglycemia, glycated hemoglobin (HbA1c), creatinine, blood urea nitrogen (BUN), triglyceride and restored the histopathological indices when compared with the diabetic control group. The 4-HIL increased the activities of antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) in tissues samples. It down-regulate the expression of vascular endothelial growth factor (VEGF), tissue injury molecule-1 (TIM-1), insulin receptor (INSULIN R) and transforming growth factor beta 1 (TGF-β1) mediated inflammatory response in all the tissues. Moreover, it exhibits protective effect against oxidative stress by activation of nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway-related proteins in the tissues.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0007" role="conclusion" view="all">
               <ce:section-title id="cesectitle0007">Conclusion</ce:section-title>
               <ce:simple-para id="spara012" view="all">The findings highlight the beneficial role of 4-HIL in diabetic complications by decreasing inflammatory response and oxidative stress through TGF-β1 signaling pathway and activation of Nrf2 gene expression respectively in addition to its effect on glycemic control.</ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract id="abs0003" class="graphical" view="all">
            <ce:section-title id="cesectitle0008">Graphical abstract</ce:section-title>
            <ce:abstract-sec id="abss0008" view="all">
               <ce:simple-para id="spara013" view="all"> [Display omitted] </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:keywords id="keys0001" view="all" class="keyword">
            <ce:section-title id="cesectitle0009">Keywords</ce:section-title>
            <ce:keyword id="key0001">
               <ce:text id="cetext0002">4-hydroxyisoleucine</ce:text>
            </ce:keyword>
            <ce:keyword id="key0002">
               <ce:text id="cetext0003">Antioxidant</ce:text>
            </ce:keyword>
            <ce:keyword id="key0003">
               <ce:text id="cetext0004">Diabetic complication</ce:text>
            </ce:keyword>
            <ce:keyword id="key0004">
               <ce:text id="cetext0005">Inflammation</ce:text>
            </ce:keyword>
            <ce:keyword id="key0005">
               <ce:text id="cetext0006">Oxidative stress</ce:text>
            </ce:keyword>
         </ce:keywords>
         <ce:keywords id="keys0002" class="abr" view="all">
            <ce:section-title id="cesectitle0010">Abbreviations</ce:section-title>
            <ce:keyword id="key0006">
               <ce:text id="cetext0007">T2DM</ce:text>
               <ce:keyword id="key7a">
                  <ce:text id="cetext7a">Type 2 diabetes mellitus</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0007">
               <ce:text id="cetext0008">4-HIL</ce:text>
               <ce:keyword id="key8a">
                  <ce:text id="cetext8a">4 - Hydroxy isoleucine</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0008">
               <ce:text id="cetext0009">STZ</ce:text>
               <ce:keyword id="key9a">
                  <ce:text id="cetext9a">Streptozotocin</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0009">
               <ce:text id="cetext0010">DN</ce:text>
               <ce:keyword id="key10a">
                  <ce:text id="cetext10a">Diabetic Nephropathy</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0010">
               <ce:text id="cetext0011">DR</ce:text>
               <ce:keyword id="key11a">
                  <ce:text id="cetext11a">Diabetic Retinopathy</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0011">
               <ce:text id="cetext0012">ROS/RNS</ce:text>
               <ce:keyword id="key12a">
                  <ce:text id="cetext12a">Reactive oxygen/nitrogen species</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0012">
               <ce:text id="cetext0013">INSULIN R</ce:text>
               <ce:keyword id="key13a">
                  <ce:text id="cetext13a">Insulin receptor</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0013">
               <ce:text id="cetext0014">VEGF</ce:text>
               <ce:keyword id="key14a">
                  <ce:text id="cetext14a">Vascular endothelial growth factor</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0014">
               <ce:text id="cetext0015">TIM-1</ce:text>
               <ce:keyword id="key15a">
                  <ce:text id="cetext15a">Tissue injury molecule-1</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0015">
               <ce:text id="cetext0016">TGF-β1</ce:text>
               <ce:keyword id="key16a">
                  <ce:text id="cetext16a">Transforming growth factor beta 1</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0016">
               <ce:text id="cetext0017">Nrf2</ce:text>
               <ce:keyword id="key17a">
                  <ce:text id="cetext17a">Nuclear factor erythroid 2-related factor 2</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0017">
               <ce:text id="cetext0018">BUN</ce:text>
               <ce:keyword id="key18a">
                  <ce:text id="cetext18a">Blood urea nitrogen</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0018">
               <ce:text id="cetext0019">HbA1c</ce:text>
               <ce:keyword id="key19a">
                  <ce:text id="cetext19a">Glycated hemoglobin</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0019">
               <ce:text id="cetext0020">SGPT</ce:text>
               <ce:keyword id="key20a">
                  <ce:text id="cetext20a">Serum glutamic pyruvic transaminase</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0020">
               <ce:text id="cetext0021">PAS</ce:text>
               <ce:keyword id="key21a">
                  <ce:text id="cetext21a">Periodic acid–Schiff</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0021">
               <ce:text id="cetext0022">LDL</ce:text>
               <ce:keyword id="key22a">
                  <ce:text id="cetext22a">Low-density lipoprotein</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0022">
               <ce:text id="cetext0023">HDL</ce:text>
               <ce:keyword id="key23a">
                  <ce:text id="cetext23a">High-density lipoprotein</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0023">
               <ce:text id="cetext0024">AGEs</ce:text>
               <ce:keyword id="key24a">
                  <ce:text id="cetext24a">Advanced glycated end products</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0024">
               <ce:text id="cetext0025">ALT</ce:text>
               <ce:keyword id="key25a">
                  <ce:text id="cetext25a">Alanine transaminase, SOD, Superoxide dismutase</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0025">
               <ce:text id="cetext0026">CAT</ce:text>
               <ce:keyword id="key26a">
                  <ce:text id="cetext26a">Catalase</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0026">
               <ce:text id="cetext0027">GSH</ce:text>
               <ce:keyword id="key27a">
                  <ce:text id="cetext27a">Glutathione</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="key0027">
               <ce:text id="cetext0028">H &amp; E</ce:text>
               <ce:keyword id="key28a">
                  <ce:text id="cetext28a">Hematoxylin – Eosin</ce:text>
               </ce:keyword>
            </ce:keyword>
         </ce:keywords>
      </ja:head>
   </ja:article>
</doc:document>
